NewAmsterdam Pharma Company N.V.

NasdaqGM:NAMS Stock Report

Market Cap: US$2.4b

NewAmsterdam Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:NAMS Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
16 Dec 24SellUS$27,400Forbion Capital Partners B.V.Company1,096US$25.00
13 Dec 24BuyUS$85,250,441Frazier Life Sciences Management, LPCompany3,689,475US$24.50
13 Dec 24SellUS$2,647,107Forbion Capital Partners B.V.Company104,409US$26.18
13 Dec 24SellUS$364,635Forbion Capital Partners B.V.Company14,441US$25.25
11 Dec 24SellUS$6,584,161Forbion Capital Partners B.V.Company259,252US$27.11
18 Nov 24SellUS$587,646Forbion Capital Partners B.V.Company23,443US$25.08
14 Nov 24SellUS$260,809Forbion Capital Partners B.V.Company10,430US$25.01
26 Sep 24BuyUS$17,333Juliette AudetIndividual1,104US$15.70
20 Aug 24BuyUS$81,350Michael DavidsonIndividual5,000US$16.27
20 Jun 24BuyUS$86,309Michael DavidsonIndividual5,000US$17.26
26 Mar 24BuyUS$181,224Frazier Life Sciences Management, LPCompany8,429US$21.50
13 Feb 24BuyUS$95,000Louis LangeIndividual5,000US$19.00

Insider Trading Volume

Insider Buying: NAMS insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of NAMS?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,103,4261.19%
Private Companies2,500,7072.71%
General Public3,610,7893.91%
Hedge Funds8,024,5658.69%
Institutions31,682,82434.3%
VC/PE Firms45,463,56149.2%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.2%.

Top Shareholders

Top 25 shareholders own 87.84% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
17.2%
Frazier Life Sciences Management, LP
15,916,418US$405.9m23.8%15.87%
11.9%
Forbion Capital Partners B.V.
11,009,230US$280.7m-6.95%49.01%
11.3%
Bain Capital Life Sciences Investors, LLC
10,473,913US$267.1m0%28.74%
8.73%
RA Capital Management, L.P.
8,064,000US$205.6m0%2.56%
8.69%
Viking Global Investors LP
8,024,565US$204.6m0%0.72%
4.4%
The Morningside Group Limited
4,060,923US$103.6m0%19.21%
3.11%
Medicxi Ventures (UK) LLP
2,869,565US$73.2m0%14.43%
2.7%
Forbion International Management B.V.
2,498,438US$63.7m0%no data
2.67%
Cormorant Asset Management, LP
2,470,000US$63.0m7.39%3.47%
1.67%
Janus Henderson Group plc
1,540,729US$39.3m51.1%0.02%
1.65%
BVF Partners L.P.
1,521,948US$38.8m0%1.25%
1.63%
Polar Capital Holdings Plc
1,505,000US$38.4m50.1%0.14%
1.49%
Adage Capital Management, L.P.
1,380,000US$35.2m-9.8%0.06%
1.26%
Woodline Partners LP
1,164,677US$29.7m141%0.26%
1.1%
Jennison Associates LLC
1,020,278US$26.0m8.87%0.01%
1.1%
Pictet Asset Management Limited
1,016,847US$25.9m48.7%0.02%
1%
Artal Group S.A.
920,564US$23.5m15.1%0.71%
0.98%
Deerfield Management Company, L.P. Series C
901,750US$23.0m3.74%0.41%
0.96%
Avidity Partners Management, L.P.
889,700US$22.7m59.1%1.32%
0.9%
GMT Capital Corp.
829,036US$21.1m-7.04%0.66%
0.89%
Michael Davidson
818,563US$20.9m0.61%no data
0.73%
Medical Strategy GmbH, Asset Management Arm
671,177US$17.1m0%1.06%
0.64%
Decheng Capital LLC
590,000US$15.0m47.5%3.66%
0.57%
Citadel Advisors LLC
522,465US$13.3m144%0.01%
0.51%
Affinity Asset Advisors, LLC
472,390US$12.0m11.6%2.14%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 01:44
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NewAmsterdam Pharma Company N.V. is covered by 11 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Judah FrommerCredit Suisse
Debjit ChattopadhyayGuggenheim Securities, LLC
Yuchen DingJefferies LLC